RARRES1 attenuates H₂O₂-induced RPE cell injury and inhibits choroidal neovascularization.

Area of Science:

• Ophthalmology
• Molecular Biology
• Biochemistry

Background:

• Neovascular age-related macular degeneration (nAMD) is a primary cause of vision loss in older adults.
• The molecular underpinnings of nAMD are not fully understood, necessitating new biomarkers and treatments.
• Retinoic acid receptor responder protein 1 (RARRES1) is investigated as a potential factor in nAMD pathogenesis.

Purpose of the Study:

• To identify and functionally characterize RARRES1 as a potential biomarker and therapeutic target for nAMD.
• To investigate the role of RARRES1 in oxidative stress, inflammation, and angiogenesis relevant to nAMD.

Main Methods:

• Proteomic analysis of aqueous humor from nAMD patients and controls.
• Assessment of RARRES1 expression in vitro and in vivo models of nAMD.
• Functional assays evaluating RARRES1's effects on retinal pigment epithelial cells and endothelial cells.
• In vivo studies using an intraocular delivery system for RARRES1 in a mouse model of choroidal neovascularization (CNV).

Main Results:

• RARRES1 levels were significantly decreased in nAMD patients and relevant disease models.
• RARRES1 overexpression protected retinal cells from oxidative stress and suppressed inflammatory and angiogenic factors.
• RARRES1 inhibited human umbilical vein endothelial cell proliferation, migration, and tube formation.
• Intraocular RARRES1 delivery reduced lesion size and vascular leakage in a mouse CNV model.

Conclusions:

• RARRES1 demonstrates protective effects against oxidative stress in retinal pigment epithelial cells.
• RARRES1 acts to inhibit key pathways involved in choroidal neovascularization.
• RARRES1 is identified as a promising biomarker and therapeutic target for nAMD.